Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice

Endogenous 4-1BB Ligand Plays a Critical Role in Protection from Influenza-Induced Disease

(2014) G. H. Y. Lin et al.   JOURNAL OF IMMUNOLOGY

CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells

(2010) H. Narazaki et al.   BLOOD

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD8+T cell concentration determines their efficiency in killing cognate antigen–expressing syngeneic mammalian cells in vitro and in mouse tissues

(2010) Sadna Budhu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination

(2009) C. A. Klebanoff et al.   BLOOD

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

(2009) R. Houot et al.   BLOOD

Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel Form of 4-1BB Ligand Eradicates Established Tumors

(2009) R. K. Sharma et al.   CANCER RESEARCH

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

(2009) Oihana Murillo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity

(2009) Y. Zhao et al.   JOURNAL OF IMMUNOLOGY

4-1BB Functions As a Survival Factor in Dendritic Cells

(2009) B. K. Choi et al.   JOURNAL OF IMMUNOLOGY

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity

(2009) C. S. Hinrichs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity

(2009) Rich-Henry Schabowsky et al.   VACCINE

Modeling the CD8+ T Effector to Memory Transition in Adoptive T-Cell Antitumor Immunotherapy

(2008) C. E. Rolle et al.   CANCER RESEARCH

The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer

(2008) David H. Lynch   IMMUNOLOGICAL REVIEWS

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION